Compare AbbVie Inc (ABBV) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AbbVie Inc vs Huntington Bancshares Incorporated — how do they compare? AbbVie Inc trades at $248.45 (market cap $441.94B), while Huntington Bancshares Incorporated trades at $17.81 (market cap $35.93B). The key difference: AbbVie Inc is far larger — about 12.3× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.49%). Which is the better fit depends on your goals.
| ABBV | HBAN | |
|---|---|---|
Market Cap | $441.94B | $35.93B |
Sector | Health | Financials |
52-Week High | $263.58 | $19.27 |
52-Week Low | $197.38 | $15.02 |
Enterprise Value | $506.19B | — |
Dividend Yield | 2.77% | 3.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.
Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.
Huntington Bancshares (HBAN) trades at $17.82, up 1.25% recently, with a bullish technical outlook and mixed earnings history. The company reported Q2 2026 EPS of $0.33, missing estimates, but revenue growth to $8.13B in 2025 supports a net income margin of 24.77%. Analysts maintain a consensus price target of $19.78, with 45% recommending Buy, amid concerns over rising deposit costs noted in recent news.
HBAN offers potential upside with a reasonable P/E of 13.68 and dividend yield, but faces risks from expense pressures and competitive banking dynamics. The stock's outlook hinges on execution of its ROTCE target of 18-19% by 2027, balancing growth opportunities with macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
